摘要
目的探究缬沙坦+贝那普利治疗对早期糖尿病肾病患者肾功能指标的影响。方法选该院2017年1月—2021年2月收治的99例早期糖尿病肾病患者为研究对象,依据随机数表法分为对照组(n=49)和观察组(n=50),分别应用缬沙坦治疗、缬沙坦+贝那普利治疗,比较两组治疗前后血糖水平[空腹血糖(FPG)、糖化红蛋白(HbA1c)]、肾功能指标[血肌酐(Scr)、尿素氮(BUN)、24 h尿蛋白排泄率(24 h UAER)、肾小球滤过率(eGFR)]、炎症因子[白细胞介素-6(IL-6)、肿瘤细胞坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)]、氧化应激反应[丙二醛(MDA)、超氧化物歧化酶(SOD)、髓过氧化物酶(MPO)]及药物不良反应发生率。结果①血糖水平:治疗前两组血糖水平相近,差异无统计学意义(P>0.05);治疗后观察组FPG、HbA1c水平较对照组低,差异有统计学意义(P<0.05);②肾功能指标:治疗前两组肾功能指标水平相近,差异无统计学意义(P>0.05);治疗后观察组Scr、BUN、24 h UAER水平较对照组低,差异有统计学意义(P<0.05),治疗后两组eGFR水平相近,差异无统计学意义(P>0.05);③炎症因子:治疗前两组炎症因子水平相近,差异无统计学意义(P>0.05);治疗后观察组IL-6、TNF-α、hs-CRP水平较对照组低,差异有统计学意义(P<0.05);④氧化应激反应:治疗前两组氧化应激反应水平相近,差异无统计学意义(P>0.05);治疗后观察组SOD水平较对照组高,MDA、MPO水平较对照组低,差异有统计学意义(P<0.05);⑤不良反应:观察组治疗不良反应发生率为14.00%,与对照组8.16%相近,差异无统计学意义(P>0.05)。结论对早期糖尿病肾病患者应用缬沙坦+贝那普利治疗,可改善患者血糖状态、肾功能指标,降低氧化应激反应及炎症影子水平,治疗效果安全理想。
Objective To explore the effect of valsartan+benazepril on renal function indexes in patients with early diabetic nephropathy.Methods From January 2017 to February 2021,99 patients with early diabetic nephropathy in the hospital were selected as the research objects.According to the random number table method,they were divided into a control group(n=49)and an observation group(n=50).Sartan treatment,valsartan+benazepril treatment,comparison of blood glucose levels[fasting blood glucose(FPG),glycosylated globin(HbA1c)],renal function indexes[serum creatinine(Scr),urea nitrogen(BUN),24 h urine protein excretion rate(24 h UAER),glomerular filtration rate(eGFR)],inflammatory factors[interleukin-6(IL-6),tumor cell necrosis factor-α(TNF-α),hypersensitivity C-reactive protein(hs-CRP)],oxidative stress response[malondialdehyde(MDA),superoxide dismutase(SOD),myeloperoxidase(MPO)]and the incidence of adverse drug reactions before and after treatment between the two groups.Results 1.Glucose level:the blood glucose levels of the two groups before treatment were similar,the difference was not statistically significant(P>0.05);after treatment,the FPG and HbA1c levels of the observation group were lower than those of the control group,the difference was statistically significant(P<0.05);2.renal function indexes:the levels of renal function indexes of the two groups before treatment were similar,the difference was not statistically significant(P>0.05);Scr,BUN,and 24 h UAER levels in the observation group after treatment were lower than those in the control group,the difference was statistically significant(P<0.05),and the eGFR levels in the two groups after treatment were similar,the difference was not statistically significant(P>0.05);3.Inflammatory factors:levels of inflammatory factors in the two groups before treatment similar,the difference was not statistically significant(P>0.05).After treatment,the levels of IL-6,TNF-α,and hs-CRP in the observation group were lower than those in the control group,the difference was statistically significant(P<0.05);4.Oxidative stress response:the oxidative stress response levels of the two groups before treatment were similar,the difference was not statistically significant(P>0.05).After treatment,the SOD level of the observation group was higher than that of the control group,and the levels of MDA and MPO were lower than those of the control group,the difference was statistically significant(P<0.05);Adverse reactions:the incidence of adverse reactions in the observation group was 14.00%,compared with 8.16%of the control group,being similar,the difference was not statistically significant(P>0.05).Conclusion The application of valsartan+benazepril to patients with early diabetic nephropathy can improve the patient's blood glucose status,renal function indicators,reduce oxidative stress and inflammation shadow levels,and the therapeutic effect is safe and ideal.
作者
林丽华
LIN Lihua(Department of Nephrology,Shaxian General Hospital,Sanming City,Fujian Province,Sanming,Fujian Province,365050 China)
出处
《糖尿病新世界》
2021年第12期19-23,共5页
Diabetes New World Magazine
